NanoVibronix, Inc. Stock News

TYLER, Texas--(BUSINESS WIRE)--NanoVibronix, Inc. (NASDAQ: NAOV) ("NanoVibronix" or the "Company"), a medical technology company specializing in non-invasive therapeutic systems, today issued a letter to shareholders, highlighting the Company's strategic vision, market opportunities and a rebranding initiative. Dear Shareholders, Since assuming the role of CEO in June 2025, our team has complet...

TYLER, Texas--(BUSINESS WIRE)--NanoVibronix, Inc. (NASDAQ: NAOV) (“NanoVibronix” or the “Company”), a medical technology company specializing in non-invasive therapeutic systems, today announced the launch of Oscar, an advanced training aid, introduced through its ENvue Medical (“ENvue” or “ENvue Medical”) division. Oscar is designed to provide clinicians and educators with a standardized, repe...

TYLER, Texas--(BUSINESS WIRE)--NanoVibronix, Inc. (NASDAQ: NAOV) (“NanoVibronix” or the “Company”), a medical technology company specializing in non-invasive therapeutic systems, today announced that it has entered into a definitive agreement with a single institutional investor for the purchase and sale of 291,204 shares of its common stock (or common stock equivalents), at an offering price o...

TYLER, Texas--(BUSINESS WIRE)--NanoVibronix, Inc. (NASDAQ: NAOV) (“NanoVibronix” or the “Company”), a medical technology company specializing in non-invasive therapeutic systems, today announced that the United States Patent and Trademark Office issued U.S. Patent No. 12,409,105 B2, titled “Insertion Device Positioning Guidance System and Method” on September 9, 2025 to ENvue Medical Holdings L...

TYLER, Texas--(BUSINESS WIRE)--NanoVibronix, Inc. (NASDAQ: NAOV) (“NanoVibronix” or the “Company”), a medical technology company specializing in non-invasive therapeutic systems, today announced that the United States Patent and Trademark Office issued U.S. Patent No. 12,402,953 B2, titled “Insertion Device Positioning Guidance System and Method” on September 2, 2025 to ENvue Medical Holdings L...

TYLER, Texas--(BUSINESS WIRE)--NanoVibronix, Inc. (NASDAQ: NAOV) (“NanoVibronix” or the “Company”), a medical technology company specializing in non-invasive therapeutic devices, today announced that it intends to effect a reverse stock split of its common stock, par value $0.001 per share (the “common stock”) at a ratio of 1 post-split share for every 10 pre-split shares. The reverse stock spl...

TYLER, Texas--(BUSINESS WIRE)--NanoVibronix, Inc. (NASDAQ: NAOV) (“NanoVibronix” or the “Company”), a medical technology company specializing in therapeutic devices for enteral feeding, pain management and urological conditions, today announced it has entered into a definitive agreement with an institutional investor for the purchase and sale of 8,889 shares of Series H Convertible Preferred St...

TYLER, Texas--(BUSINESS WIRE)--NanoVibronix, Inc. (NASDAQ: NAOV) (“NanoVibronix” or the “Company”), a medical technology company specializing in non-invasive therapeutic systems, today announced the official launch of a next-generation robotic development initiative within its ENvue Medical (“ENvue” or “ENvue Medical”) division. The new platform, ENvue Drive™, is being developed to automate ele...